Below is the first part of an article from marketwatch.com. It reads…
NEW YORK, Jul 10, 2014 (GLOBE NEWSWIRE via COMTEX) —
Pomerantz LLP has filed a class action lawsuit against Regado Biosciences, Inc. (“Regado” or the “Company”) RGDO +3.98% and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-04345-JAP-DEA, is on behalf of a class consisting of all persons or entities who purchased Regado securities between August 22, 2013 and July 9, 2014, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
If you are a shareholder who purchased Regado securities during the Class Period, you have until September 8, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at firstname.lastname@example.org or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
Regado is a biopharmaceutical company that focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular and other indications.